DiaSorin’s COVID-19 Test Receives FDA Emergency Use Authorization
By HospiMedica International staff writers Posted on 02 Apr 2020 |
Image: LIAISON® MDX (Photo courtesy of DiaSorin Molecular LLC)
DiaSorin Molecular LLC (Cypress, CA, USA) has received Emergency Use Authorization (EUA) from the FDA for its Simplexa COVID-19 Direct kit. The kit provides a sample-to-answer test for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, directly from nasopharyngeal swab specimens.
DiaSorin manufactures and distributes molecular diagnostic products for hospital and reference laboratories. The company’s products help laboratories consolidate their testing, streamline processes and increase efficiency. DiaSorin’s Simplexa molecular diagnostic kits are designed for use on the company’s versatile LIAISON MDX platform. It also markets a range of ASRs (analyte-specific reagents) for use in lab-developed tests. DiaSorin received federal funds from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the US Department of Health and Human Services, in order to develop its Simplexa COVID-19 Direct kit which is designed for use on the LIAISON MDX.
The Simplexa COVID-19 Direct kit contains an all-in-one reagent mix which is ready to use. Only one instrument and one reagent are required to perform the test. It bypasses the need for traditional extraction procedures, enabling rapid detection in a little over an hour which is significantly faster than the up to seven hours currently required by traditional extraction followed by amplification technologies, ultimately allowing prompt decision making regarding isolation of infected patients. It can be utilized by hospital laboratories without the need to send the sample out, allowing for timely testing and results. The test is highly specific to COVID-19 and targets several regions of the viral genome to minimize the impact on performance should there be possible future mutations. This ensures the results are highly sensitive and specific providing confidence in diagnostic decision-making.
“We are excited for the launch of our COVID-19 test and hope to help reduce the current shortage of tests being experienced by hospitals worldwide” said John Gerace, president of DiaSorin Molecular. “This test will better enable clinicians to make appropriate diagnostic decisions by providing rapid and accurate results. We know it will play a critical role in containing the pandemic.”
Related Links:
DiaSorin Molecular LLC
DiaSorin manufactures and distributes molecular diagnostic products for hospital and reference laboratories. The company’s products help laboratories consolidate their testing, streamline processes and increase efficiency. DiaSorin’s Simplexa molecular diagnostic kits are designed for use on the company’s versatile LIAISON MDX platform. It also markets a range of ASRs (analyte-specific reagents) for use in lab-developed tests. DiaSorin received federal funds from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the US Department of Health and Human Services, in order to develop its Simplexa COVID-19 Direct kit which is designed for use on the LIAISON MDX.
The Simplexa COVID-19 Direct kit contains an all-in-one reagent mix which is ready to use. Only one instrument and one reagent are required to perform the test. It bypasses the need for traditional extraction procedures, enabling rapid detection in a little over an hour which is significantly faster than the up to seven hours currently required by traditional extraction followed by amplification technologies, ultimately allowing prompt decision making regarding isolation of infected patients. It can be utilized by hospital laboratories without the need to send the sample out, allowing for timely testing and results. The test is highly specific to COVID-19 and targets several regions of the viral genome to minimize the impact on performance should there be possible future mutations. This ensures the results are highly sensitive and specific providing confidence in diagnostic decision-making.
“We are excited for the launch of our COVID-19 test and hope to help reduce the current shortage of tests being experienced by hospitals worldwide” said John Gerace, president of DiaSorin Molecular. “This test will better enable clinicians to make appropriate diagnostic decisions by providing rapid and accurate results. We know it will play a critical role in containing the pandemic.”
Related Links:
DiaSorin Molecular LLC
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans